IQVIA Holdings Inc. (NYSE:IQV) Stake Boosted by Fulton Bank N.A.

Fulton Bank N.A. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 44.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,969 shares of the medical research company’s stock after purchasing an additional 1,527 shares during the quarter. Fulton Bank N.A.’s holdings in IQVIA were worth $1,178,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IQV. Ossiam lifted its stake in IQVIA by 8.4% during the fourth quarter. Ossiam now owns 10,119 shares of the medical research company’s stock worth $2,341,000 after purchasing an additional 784 shares during the last quarter. Shell Asset Management Co. bought a new stake in IQVIA in the fourth quarter valued at $1,135,000. Elo Mutual Pension Insurance Co raised its stake in shares of IQVIA by 2.9% during the fourth quarter. Elo Mutual Pension Insurance Co now owns 15,988 shares of the medical research company’s stock valued at $3,699,000 after purchasing an additional 444 shares in the last quarter. Cadian Capital Management LP bought a new stake in shares of IQVIA during the fourth quarter valued at about $70,108,000. Finally, L1 Capital International Pty Ltd bought a new stake in shares of IQVIA during the fourth quarter valued at about $5,011,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.9 %

Shares of IQVIA stock opened at $225.36 on Tuesday. The firm has a market cap of $41.08 billion, a price-to-earnings ratio of 30.79, a P/E/G ratio of 2.18 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a 50-day simple moving average of $240.74 and a 200-day simple moving average of $232.41.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.22 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IQV. Barclays lifted their target price on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Truist Financial lifted their price target on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Robert W. Baird lifted their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Morgan Stanley lifted their price target on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Finally, Evercore ISI lifted their price target on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.